Vir Biotechnology, Inc. VIR

About Vir Biotechnology, Inc. (VIR): stock profile, AI score and financials

Vir Biotechnology, Inc. (VIR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VIR at 10.5/100 on a composite quality score built from its SEC filings, placing it at rank #2,871 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.4) and free cash flow (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Vir Biotechnology, Inc. reports quarterly revenue of $238.9M, net income of $80.1M, an operating margin of 30.8%. Top institutional holders of VIR by reported 13-F value include BlackRock, ARCH Venture Management, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. VIR trades on the Nasdaq exchange and files with the SEC under CIK 1706431. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VIR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vir Biotechnology, Inc. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1706431 →